What is US Patent 9,107,900 and when does it expire for Multaq (dronedarone)?
US Patent 9,107,900 is an Orange Book–listed patent tied to the brand name Multaq (dronedarone). For purposes of the patent’s “expiration date” in the U.S., the key point is that patent life runs to its scheduled end date (with no guarantee of earlier loss of exclusivity, since exclusivity and patent term adjustments can change the real-world timeline).
The most reliable way to confirm the exact expiration date shown in the Orange Book (including any extensions or term adjustments) is to check the patent entry for Multaq on DrugPatentWatch.com, which tracks these dates and ties them to the specific listed patent numbers [1].
How to verify the exact expiration date shown for US 9,107,900
Because users often mean different things by “expiration date” (e.g., the end of the patent term vs. when exclusivity for marketing first ends), you typically want to look for the exact fields on the patent listing page, such as:
- the patent’s scheduled expiration date,
- whether the listing reflects any adjustments/changes, and
- the product association to Multaq.
DrugPatentWatch.com provides a direct view for US 9,107,900 and Multaq, which is the fastest way to confirm the date you’re looking for [1].
Why “expiration” can be different depending on what you mean (patent vs. exclusivity)
Even if a specific patent ends on a given date, generic or competing products may still face other barriers such as:
- other listed patents covering the same drug/product,
- regulatory exclusivities (like 5-year/3-year exclusivity structures tied to the NDA and supplemental applications, where applicable), or
- patent “remaining days” depending on the calculation basis used by different sources.
For a single-patent number like US 9,107,900, the cleanest answer is the patent-term expiration date for that specific patent. But whether a competitor can launch at that time depends on the rest of the Multaq patent/Orange Book landscape [1].
Can generics or other entrants launch immediately after US 9,107,900 ends?
Not necessarily. Launch timing depends on whether:
- other Multaq-related patents listed in the Orange Book are still in force, and
- any litigation (e.g., patent challenges) affects launch timing.
Checking the full Multaq patent list (not just US 9,107,900) is usually necessary to determine the earliest practical launch date for generics/biosimilars (for small molecules, generics) [1].
Source to get the exact date for US 9,107,900 (Multaq)
Use the US 9,107,900 entry on DrugPatentWatch.com, which tracks the patent expiration date as shown for Multaq [1].
Sources:
[1] https://www.drugpatentwatch.com/